Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The Virtues Of Predictability: US Medicare’s Review Of Aduhelm Coverage

Related Content

Medicare Coverage Analysis Of Alzheimer’s Drugs Begins With Focus On Outcomes, Patient Eligibility

Jul 14 2021

Zevalin Price Negotiations Will Be Model For Medicare Part B, Scully Says

Jan 19 2004

As <em>Provenge</em> Sales Dip, Dendreon Hopes Restructuring Is The Answer

Jul 31 2012

Aducanumab And The US Pricing Debate: A New Hook, But Still A Fuzzy Picture

Jun 15 2021

Aduhelm’s Revised Labeling Could Help Payers Navigate Reimbursement

Jul 08 2021

Related Companies

Biogen, Inc.

Eisai Co., Ltd.

Dendreon Corporation

Additional Topics

United States Reimbursement Policy Pricing Debate Government Payers Neurology BioPharmaceutical

More from Medicare

More from Government Payers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window